Phase I, First-in-Human Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of (ML-246) in Patients With Metastatic Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I trial is to find a safe dose of metarrestin and to see if this dose shrinks tumors.
General Information
NCT#: NCT04222413
Study ID: 200023
Trial Phase: Phase I
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Metarrestin